Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 50 of 50 matching drugs for PSMD1 — including drugs targeting any of its 109 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
bortezomib PSMD1 Direct yes 0
carfilzomib PSMD1 Direct yes 0
ixazomib PSMD1 Direct yes 0
ixazomib citrate PSMD1 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
alendronate, etidronate, ibandronate, risedronate, raloxifene FDPS SSL via FDPS 2
selinexor XPO1 SSL via XPO1 yes 2
aldesleukin, therapeutic autologous lymphocytes, zoledronic acid FDPS SSL via FDPS 1
biopsy, magnetic resonance imaging, radiation therapy, selinexor XPO1 SSL via XPO1 1
biospecimen collection, magnetic resonance imaging, selinexor, temozolomide XPO1 SSL via XPO1 1
capecitabine, fluorouracil, laboratory biomarker analysis, pharmacological study, stereotactic body radiation therapy, zoledronic acid FDPS SSL via FDPS 1
disulfiram, copper, alkylating agents EIF4A1 SSL via EIF4A1 1
disulfiram, copper, alkylating agents EIF6 SSL via EIF6 1
gemcitabine hydrochloride, selinexor, pharmacological study, laboratory biomarker analysis, nab paclitaxel XPO1 SSL via XPO1 1
imab362, zoledronic acid, interleukin-2 (1 million iu), interleukin-2 (3 million iu) FDPS SSL via FDPS 1
pharmacological study, selinexor XPO1 SSL via XPO1 1
selinexor, acetaminophen XPO1 SSL via XPO1 1
selinexor, temozolomide, generic radiation therapy (rt), selective serotonin receptor (5-ht3) antagonists, olanzapine, salt tablets, anti-diarrheal XPO1 SSL via XPO1 1
afatinib dimaleate EGFR SSL via EGFR yes 0
alendronate sodium FDPS SSL via FDPS yes 0
alendronic acid FDPS SSL via FDPS yes 0
carfilzomib PSMB6 SSL via PSMB6 yes 0
cetuximab EGFR SSL via EGFR yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
ibandronate sodium FDPS SSL via FDPS yes 0
ixazomib PSMB6 SSL via PSMB6 yes 0
ixazomib citrate PSMB6 SSL via PSMB6 yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
metformin NDUFA8 SSL via NDUFA8 yes 0
metformin hydrochloride NDUFA8 SSL via NDUFA8 yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
pamidronate disodium FDPS SSL via FDPS yes 0
pamidronic acid FDPS SSL via FDPS yes 0
panitumumab EGFR SSL via EGFR yes 0
regorafenib EGFR SSL via EGFR yes 0
risedronate sodium FDPS SSL via FDPS yes 0
risedronic acid FDPS SSL via FDPS yes 0
vandetanib EGFR SSL via EGFR yes 0
zoledronic acid FDPS SSL via FDPS yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.